triCitrasol® Anticoagulant Sodium Citrate Concentrate
Anticoagulant for Granulocytapheresis Procedures
triCitrasolÌýAnticoagulant Sodium Citrate Concentrate, 46.7%ÌýTrisodiumÌýCitrate (30.5% free citrate ion), is a sterile, non-pyrogenic solution, used inÌýgranulocytapheresisÌýprocedures (granulocyte collection by apheresis).
Procedures
- Granulocytapheresis
Philosophies
- Pharmaceuticals
Application
- Multiple
Product Features
Prior to performingÌýgranulocytapheresis, 30 mL of theÌýtriCitrasolÌýConcentrate is aseptically added to 500 mL of the solution 6% Hydroxyethyl Starch (HES).Ìý
The final solution prevents the coagulation of blood by virtue of the citrate ion's ability to chelate ionized calcium present in the blood to form a non-ionized calcium-citrate complex. When the total dose of citrate ions is greater than the total amount of ionized calcium, clottingÌýis prevented.
Benefits
Preventing Clotting
- Final solution prevents coagulation of bloodÌýthrough theÌýcitrate ion's ability to chelate ionized calcium present in the blood to form a non-ionized calcium-citrate complex. When total dose of citrateÌýions is greater than total amount of ionized calcium, clottingÌýis prevented.
FDA Approved
- triCitrasolÌýConcentrate was approved by the US Food & DrugÌýAdminsitrationÌý(FDA) in 2003
Important Safety Information
Indications
triCitrasolÌýConcentrate is an anticoagulant used inÌýgranulocytapheresisÌýprocedures.
Warnings and Contraindications
triCitrasolÌýConcentrate is not for direct intravenous infusion.
triCitrasolÌýConcentrate is a concentrated anticoagulant — dilute prior to use (see full prescribing information).
Adverse reactions
Citrate reactions or toxicity may occur with the infusion of blood products containing citrate anticoagulant. The recipient of the citrated blood product should be monitored for the signs and symptoms of citrateÌýtoxicity whichÌýcan begin with tingling sensations around the mouth or in the extremities, followed by severe reactions characterized by chills, stomach cramps, or pressure in the chest, followed by more severe reactions characterized by hypotension and possible cardiac arrhythmia. Citrate toxicity may occur more frequently in patients that are hypothermic, have impaired liver or renal function, or have low calcium levels because of an underlying disease.Ìý
Ìý
Additional Information
Related Products
Legal Disclaimer
All content herein is protected by copyright, trademarks and other intellectual property rights, as applicable, owned by or licensed to 91ÖÆƬ³§ or its affiliates unless otherwise indicated, and must not be redistributed, duplicated or disclosed, in whole or in part, without the express written consent of 91ÖÆƬ³§.  Ìý
This material is intended for health care professionals. Distribution to any other recipient is prohibited.Ìý
For product information, including indications, contraindications, warnings, precautions, potential adverse effects and patient counseling information, see theÌýinstructions for use or contact your local representative; search this website for additional product information.ÌýTo obtain a copy of the current Instructions for Use (IFU) for full prescribing and risk information, please visit .ÌýFor product related questions, please call 1-800-348-2759.Ìý